NICE Backs New Targeted Therapy for Advanced Cervical Cancer
NICE has recommended tisotumab vedotin as a treatment option for advanced cervical cancer. This therapy addresses a significant unmet need for patients who have limited options after systemic treatment. The recommendation is based on clinical evidence showing improved survival and progression-free survival compared to traditional chemotherapy.
- ▪NICE has endorsed tisotumab vedotin for recurrent or metastatic cervical cancer after systemic treatment.
- ▪The therapy demonstrated a median overall survival of 11.5 months compared to 9.5 months for chemotherapy.
- ▪Adverse events were common, but severe events were less frequent with tisotumab vedotin than with chemotherapy.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/nice-backs-new-targeted-therapy-advanced-cervical-cancer-2026a1000gmb?src=rss |
| Publication time | Fri, 22 May 2026 06:41:58 EDT |
| Retrieval time | 2026-05-22T11:02:01.362Z |
| Last seen | 2026-05-22T11:02:01.362Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | ic88cAIPpzN_ |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
The National Institute for Health and Care Excellence (NICE) has recommended tisotumab vedotin (Tivdak, Genmab) as an option for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment in adults. The final draft guidance addresses what NICE describes as an unmet need for patients with advanced cervical cancer, who typically face limited therapeutic options beyond standard single-agent chemotherapy.Disease ContextCervical cancer develops when abnormal cells in the lining of the cervix grow uncontrollably and form a tumour, with human papillomavirus detected in 99.7% of cases.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
